Upload
elwin-powell
View
219
Download
0
Tags:
Embed Size (px)
Citation preview
Understanding Gene and Cell Therapy Understanding Gene and Cell Therapy Approaches for DMDApproaches for DMD
November 6 2015November 6 2015
Overview
Annemieke Aartsma-Rus
• What does dystrophin do?
• What happens when there is no dystrophin?
• How does drug development work
• What genetic approaches are in development to replace dystrophin?
• How do they work
• Challenges/opportunities
Some basic biology: genes & proteins
Annemieke Aartsma-Rus
• Proteins are building blocks of our body
• Genes contain blueprint for proteins
• Mistake in gene mistake in protein
• Genes have a volume switch (protein only produced in proper tissue)
• Dystrophin protein has a function in muscle
• Mistake in dystrophin Problems in muscle
Muscles
Annemieke Aartsma-Rus
• 30-40% of our body is muscle
• >750 different muscles
• Muscles can grow bigger or smaller
• Muscles use a lot of energy
• Only maintained when needed
• Muscles are damaged when used too much
• Muscles have efficient system to repair damage and prevent future damage (grow bigger)
Muscle contraction
Annemieke Aartsma-Rus
Muscle fibers
Annemieke Aartsma-Rus
SkeletonSkeleton
Connective tissueConnective tissue
Dystrophin
Annemieke Aartsma-Rus
• Dystrophin provides stability to muscle fibers during contraction
• Connects skeleton of muscle fibers to connective tissues surrounding muscle fibers
• No dystrophin Connection lost
• Muscle more sensitive to damage
• Chronic damage: repair system cannot keep up
• Loss of muscle tissue and function
Dystrophin
Annemieke Aartsma-Rus
DystrophinDystrophin
Duchenne: no functional dystrophin
Annemieke Aartsma-Rus
What happens without dystrophin
Annemieke Aartsma-Rus
InflammationRepair
Muscle damage
Fibrosis
Less blood flow Too much Ca2+
Oxidative stress Mitochondria damaged
Loss of muscle tissueLoss of muscle function
What are muscle cross sections?Muscle cross sectionsMuscle cross sections
Annemieke Aartsma-Rus
H&E stainingH&E stainingFibers pinkFibers pinkNuclei blueNuclei blue
Dystrophin stainingDystrophin immune staining
Annemieke Aartsma-Rus
Healthy Mdx mouse Duchenne
Revertant fibers & trace amounts
Annemieke Aartsma-Rus
Revertant Fibers
Trace amounts
Untreated DMD muscle
Western blotting
Western blotWestern blot• Proteins isolated from muscleProteins isolated from muscle• Separated by sizeSeparated by size• Stain for dystrophinStain for dystrophin
Annemieke Aartsma-Rus
DMDDMD Becker (dilutions)Becker (dilutions) Control (diluted)Control (diluted)LongLong
ShortShort
Therapy development
Annemieke Aartsma-Rus
• Dystrophin is missing• Trying to replace dystrophin
• Also many other therapies aiming at improving muscle quality/slowing down disease processes
What are cell models
Annemieke Aartsma-Rus
• Cells derived from patients • Muscle biopsies• Skin biopsies converted into muscle cells (lab)
• Expanded in the lab (limited!!)• “Immortalized” cells
• Muscle stem cells treated with viruses• Keep expanding, but have been modified
• Cell cultures are model systems• Valuable tool for early stages of research
What are mdx mice?
Annemieke Aartsma-Rus
Mdx mouse• Mutation in mouse dystrophin gene• No dystrophin protein• But….disease not very severe
• Very efficient muscle regeneration• Turns up volume switch utrophin gene in muscle
• No dsytrophin & utrophin: severe disease• (Double knockout mouse)
Other animal models
Annemieke Aartsma-Rus
Golden retriever muscular dystrophy (GRMD)• Mutation in dog dystrophin gene• No dystrophin protein• Mutation beginning gene• Severe disease (muscle & heart)• Muscle weakness, remain ambulant• Most dogs do not live > year • Severity is variable
• Rare mild individuals
Other animal models
Annemieke Aartsma-Rus
Pig model• Mutation in pig dystrophin gene• No dystrophin protein• Deletion exon 52• Severe disease (muscle & heart)
Drug testing in patients
Annemieke Aartsma-Rus
• Test compound properties• Taken up by tissues efficiently?• How quickly cleared from the body?
• Test compound for efficacy• Does it work?• At which dose?
• Test compound for safety• Are there side effects?• At which dose?• Are they tolerable?
Development of therapies
Annemieke Aartsma-Rus
• Tests from cell and animal models to clinical trials
• All steps are important to show proof-of-concept (does it work in a model system ?)
• Next steps are always more complicated
• Success in one step is no guarantee for success in subsequent steps
• Clinical trials are experiments in humans
• May not work, may not be safe
Cell therapy
Annemieke Aartsma-Rus
Muscle stem cells• Isolate muscle stem cells from healthy donor
• Expand outside the body (culture in lab)
• Transplant into patients
• Transplanted cells repair muscle
• Transplanted cells make dystrophin
Muscle stem cells (myoblasts)
Annemieke Aartsma-Rus
• Immune response (suppress)• Do not exit circulation after injection• Local injection: stay close to injection site• Tremblay (Canada): multiple local injections
• Local dystrophin restoration• Not feasible for larger muscles
Stem cell therapy
Annemieke Aartsma-Rus
Stem cells from fat, bone and bloodvessel walls • Can exit bloodstream and migrate into muscle• Very low efficiency
Mesangioblasts most promising• Encouraging results in dog model• Safety trial ongoing in Italy (Giulio Cossu) • 3 patients received stem cells• Some side effects• Preparing for injection 2 more patients
Niche
Annemieke Aartsma-Rus
InflammationRepair
Muscle damage
Fibrosis
• Dystrophic muscle is damaged (scar tissue/fibrosis)• The few transplanted stem cells that reach muscle
• Do not receive proper signals to become muscle• Receive signals from scar tissue: more fibrosis
Immunity
Annemieke Aartsma-Rus
• Transplanting cells from one person to another will elicit an immune response
• Need chronic immune suppression
• Side effects
• Isolate patient stem cells, expand in the lab, correct mutation with gene therapy & transplant
• No immune response
• Gene therapy more efficient in cultured cells than in muscles
Cell therapy summary
Annemieke Aartsma-Rus
• Opportunities
• Applicable to all patients
• Deliver dystrophin gene and repair muscle
• Currently in very early stage clinical development
• Challenges
• Efficiency very low
• Damaged muscle gives wrong signals to cells
• Immunity (only with allogenic transplantation
Gene Therapy
Annemieke Aartsma-Rus
• Add functional gene to muscle cells patients
• Dystrophin protein made from new gene
• Applicable to ALL patients
• Genes located in nucleus cells
• How to get gene into (majority) nuclei of muscle cells?
Gene Therapy
Annemieke Aartsma-Rus
Maaike van Putten
Gene Therapy
Annemieke Aartsma-Rus
Virus
• Small organism that injects genetic information into cells
• Use to deliver dystrophin gene
• Adapt
• Remove virus genes (pathogenic)
• Add new gene (dystrophin)
Gene Therapy
Annemieke Aartsma-Rus
Which virus?
• Most viruses do not infect muscle tissue
• Muscle cells do not divide often
• Lot of connective tissue (filters out viruses)
• Exception: adeno-associated virus (AAV)
• Preference for muscle
• Not pathogenic in man
Gene Therapy
Annemieke Aartsma-Rus
• Very small (20 nm, 0.00002 mm)
• Capacity: 4.500 DNA subunits
• Dystrophin gene: 2.200.000 DNA subunits
• Genetic code gene: 14.000 subunits
• Remove part from genetic code
• Only essential parts remain
Gene Therapy
Annemieke Aartsma-Rus
MicrodystrophinOnly crucial domainsFits in AAV particle
Gene Therapy
Annemieke Aartsma-Rus
Clinical trials
• Safety study in 6 Duchenne patients
• 2006/7, USA: local injection biceps (Mendell,Samulski, Xiao Xiao)
• Immune response!
• Dystrophin in 2/6 patients (very low levels)
• Prepare for bigger trial (whole muscle treatment)
Upscaling
Annemieke Aartsma-Rus
• Mouse 12 gram muscle
• Monkey 4 kg muscle
• Human boy 10-25 kg muscle
• Monkeys and humans much larger than mice
• Need much more viruses
• Manufacturing systems optimized to allow production of sufficient amounts for treating human limbs at clinical grade
333x
2-6x
Delivery
Annemieke Aartsma-Rus
• Whole animal delivery possible for mouse
• Not feasible (yet) for large animals
• Limited by amount of virus
• Produced
• Injected
• Whole limb delivery in development for human
• Hydrodynamic limb perfusion (most efficient)
• Regional limb perfusion (less damage)
Limb perfusion
Annemieke Aartsma-Rus
• Tested in monkeys and dogs with ‘color gene’
• Delivery to multiple muscles feasible
• Tested in adult MD patients with saline
• Possible for lower leg or arm (less efficient)
• Not yet tested in humans to deliver gene
Gene Therapy Summary
Annemieke Aartsma-Rus
• Opportunities
• Applicable to all patients
• Currently in early clincial development (safety/tolerability tests)
• Challenges
• Microdystrophin only partially functional
• Delivery
• Immunity
Gene/cell therapy: DNA editing
Annemieke Aartsma-Rus
• DNA has a repair system
• Activated upon DNA damage
• Use this system to correct for DNA mistakes?
Mutation
Template with correct DNA information
DNA repair system
Mistake corrected (in one cell)
DNA editing
Annemieke Aartsma-Rus
• Challenge: DNA repair system very inefficient (1 in 1,000,000 – 1,000,000,000 cells)
• Much more efficient when DNA is ‘broken’ (1 in 10-1000 cells)
Have to generate DNA breaks at/close to mutation
DNA scissor system
Annemieke Aartsma-Rus
• DNA scissors can cut DNA at specific location
Scissor cuts at/near mutation
Repair break with template(Correct small mutations)
Repair break without templateSmall mutations will be introduced (can correct genetic code like exon skipping)
DNA scissor system
Annemieke Aartsma-Rus
Combination of DNA scissors to restore genetic code
Scissors cut around exon break is repaired
Exon is deleted Genetic code restored (like exon skipping)
DNA scissor system
Annemieke Aartsma-Rus
• DNA scissors can make breaks in DNA
• Different types of scissors in development
• Zinc Fingers, TALENs and RGNs
• Challenge: deliver scissors and templates to muscles
Exon skipping
Annemieke Aartsma-Rus
NormalNormal DuchenneDuchenne
Dystrophin gene
Annemieke Aartsma-Rus
Splicing
Annemieke Aartsma-Rus
ExonsExons IntronsIntrons1
3
5
6
7 Gene (DNA)Gene (DNA)
RNA copy (pre mRNA)RNA copy (pre mRNA)
messenger RNAmessenger RNA
1 - - - - - - - - - 79
dystrophin proteindystrophin protein
SplicingSplicing
2
4
3 4 56 7
1 21 2 3 4 5 6 7 8
Duchenne: genetic code disrupted
Annemieke Aartsma-Rus
Duchenne: genetic code disrupted
Annemieke Aartsma-Rus
Protein translation stops prematurelyProtein translation stops prematurely
Dystrophin not functionalDystrophin not functional
Exon 46 Exon 47 Exon 51 Exon 52?
Becker: genetic code maintained
Annemieke Aartsma-Rus
Becker: genetic code maintained
Annemieke Aartsma-Rus
Protein translation continuesProtein translation continues
Dystrophin partly functionalDystrophin partly functionalLess damageLess damage
Exon 46 Exon 47 Exon 52 Exon 53
Exon skipping: restore genetic code
Annemieke Aartsma-Rus
Applicability
Annemieke Aartsma-Rus Aartsma-Rus Hum Mutat 2009, 30:293-9
hotspot
Exon skip chemistries
Annemieke Aartsma-Rus
• Two chemistries in clinical development
• GSK/Prosensa: 2’-O-methyl phosphorothioate (drisapirsen)
• AVI-Biopharma/Sarepta: phosphorodiamidate morpholino oligomers (eteplirsen)
• Exon 51
Exon skipping summary
Annemieke Aartsma-Rus
• Opportunities
• AON delivery easier than genes/cells
• Clinical trial results encouraging
• Challenges
• Mutation specific approach
• Need to develop many AONs to treat majority of patients
• Repeated treatment needed (also opportunity)
Stop codon readthrough
Annemieke Aartsma-Rus
1 79
PTC124/ataluren
Annemieke Aartsma-Rus
1 79
PTC
Cell ignores new stop signalCell ignores new stop signalComplete protein is madeComplete protein is made
Stop codon readthrough summary
Annemieke Aartsma-Rus
• Opportunities
• Oral delivery
• Applicable to multiple diseases
• Challenges
• Mutation specific approach (15%)